Drug intelligence / Profile preview

danlou tablet + salvia miltiorrhiza + ligustrazine

Development stage
Unknown
Lead developer
Traditional Chinese Medicine Hospital of Tailai County
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

The combination of **Danlou tablet**, **Salvia miltiorrhiza** (Danshen), and **ligustrazine** (tetramethylpyrazine) is a therapeutic regimen used in Traditional Chinese Medicine (TCM) for the treatment of cardiovascular conditions, specifically **chronic stable angina**. Danlou tablet is a standardized Chinese patent medicine composed of ten herbs (including *Trichosanthes kirilowii*, *Allium macrostemon*, and *Pueraria lobata*) designed to resolve phlegm, remove blood stasis, and unblock the collaterals. Salvia miltiorrhiza and ligustrazine (often administered together as a fixed-dose injection) provide potent synergistic effects by promoting blood circulation, inhibiting platelet aggregation, and inducing vasodilation. This combination therapy targets the 'phlegm-stasis' pathogenesis common in coronary heart disease, aiming to improve myocardial blood supply, reduce inflammatory markers like C-reactive protein and NF-kappa B, and alleviate anginal symptoms. The regimen has been studied and utilized by institutions such as the **Traditional Chinese Medicine Hospital of Tailai County** to enhance clinical outcomes in patients with stable coronary artery disease.

Brand names
Danshen Chuanxiongzine Injection
Other names
Danlou PianDanlou Tablet + Danshen + ChuanxiongzineDanlou Tablet + Salvia miltiorrhiza + Tetramethylpyrazine
02

Targets

NF-κBEPAS1 (Hypoxia-inducible factor 2-alpha)TNFA (Tumor necrosis factor alpha (soluble))NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on danlou tablet + salvia miltiorrhiza + ligustrazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on danlou tablet + salvia miltiorrhiza + ligustrazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call